Modern management of the cancer anorexia-cachexia syndrome

Current Pain and Headache Reports

Volumn 5, Issue 3, 2001, Pages 250-256

  Nelson, Kristine A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Advanced Cancer; Early Satiety; Megestrol Acetate; Prokinetic Agent; Thalidomide

Indexed keywords

APPETITE STIMULANT;

ANOREXIA; CACHEXIA; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; REVIEW; SYNDROME;

ANOREXIA; APPETITE STIMULANTS; CACHEXIA; HUMANS; NEOPLASMS; SYNDROME;

EID: 0035379544     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-001-0039-5     Document Type: Article

References (40)

1. Nelson K, Walsh D, Sheehan F: The cancer anorexia cachexia syndrome. J Clin Oncol 1994, 12:213–225.
2. Donnelly S, Walsh D: The symptoms of advanced cancer. Semin Oncol 1995, 22(suppl):67–72. This comprehensive report on a 1000-patient study of symptoms in advanced cancer is important because of the tool that was used for evaluation. Thirty-eight patient-reported symptoms are reviewed.
3. Warren S: The immediate causes of death in cancer. Am J Med Sci 1932, 184:610–615. DOI: 10.1097/00000441-193211000-00002
4. Klein S: Clinical efficacy of nutritional support in patients with cancer. Oncology 1993, 7:87–92.
5. Koch J: The role of body composition measurements in wasting syndromes. Semin Oncol 1998, 25(suppl:6):12–19. Complete review of currently available body composition measurements and their use in wasting syndromes. In addition, the author briefly reviews body composition and energy stores.
6. Regelson W, Butler JR, Schultz J, et al.: Delta-9-tetrahydrocannabinol as an effective antidepressant and appetitestimulating agent in advanced cancer patients. In The Pharmacology of Marijuana. Edited by Braude MC, Szara S. New York: Raven Press; 1976:763–775.
7. Nelson KA, Walsh D, Deeter P, Sheehan F: A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994, 10:14–18.
8. Beal JE, Olson R, Laubenstein L, et al.: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDs. J Pain Symptom Manage 1995, 10:89–97. DOI: 10.1016/0885-3924(94)00117-4
9. Mechoulam R, Feigenbaum JJ: The pharmacohistory of Cannabis sativa. In Progress in Chemistry, vol 24. Edited by Ellis GP, West GB. New York: Elsevier; 1987:160–167.
10. Joy JE, Watson SJ, Benson JA: Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press; 1999. This authoritative report from the National Institute of Medicine provides an important synthesis of the current information about medicinal use of marijuana. Comments on all of the reported uses are included, along with recommendations for further study. Clinicians interested in specific uses will find information in the book or online at www.nap.edu.
11. Walsh D, Avashia J: Glucocorticoids in clinical oncology. Cleve Clin J Med 1992, 59:505–515.
12. Twycross R: The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994, 11:163–178.
13. Moertel CG, Schutt AJ, Reitemeir RJ, et al.: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974, 33:1607–1609. DOI: 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V
14. Loprinzi CL, Kugler JW, Sloan JA, et al.: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/ cachexia. J Clin Oncol 1999, 17:3299–3306.
15. Willox JC, Corr J, Shaw J, et al.: Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984, 288:27. DOI: 10.1136/bmj.288.6410.27
16. Cuna GRD, Pellegrini A, Piazzi M: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. Eur J Cancer Clin Oncol 1990, 25:1817–1821.
17. Bruera E, Roca E, Cedaro L, et al.: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985, 69:751–754.
18. Hanks GW, Trueman T, Twycross RG: Corticosteroids in terminal cancer: a prospective analysis of current practice. Postgrad Med J 1983, 59:702–706.
19. Weissman DE, Dufer D, Vogel V, et al.: Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987, 5:125–128. DOI: 10.1007/BF02571300
20. Ellershaw JE, Kelly MJ: Corticosteroids and peptic ulceration. Palliat Med 1994, 8:222–228.
21. Carson JL, Strom BL, Schinnar R, et al.: The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 1991, 91:223–228. DOI: 10.1016/0002-9343(91)90119-I
22. Stiefel FC, Breitbart WS, Holland JC: Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989, 7:479–491.
23. Bruera E, Macmillan K, Kuehn N, et al.: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66:1279–1282. DOI: 10.1002/1097-0142(19900915)66:6<1279::AID-CNCR2820660630>3.0.CO;2-R
24. Loprinzi CL, Michalak JC, Schaid DJ, et al.: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993, 11:762–767.
25. Donnelly S, Walsh D: Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Manage 1995, 10:182–183. DOI: 10.1016/0885-3924(94)00119-6
26. DeConno F, Martini C, Zecca E, et al.: Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer 1998, 34:1705–1709. DOI: 10.1016/S0959-8049(98)00219-6
27. McMillan DC, Wigmore SJ, Fearon KCH, et al.: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999, 79:495–500. Although this reported study is small and has a significant dropout rate, it remains important because of the use of ibuprofen to suppress the acute phase reaction known to be a major factor in the anorexiacachexia syndrome. Findings from this study demonstrate the possibility that suppressing the acute phase response may help to stabilize weight loss. DOI: 10.1038/sj.bjc.6690077
28. Nathwani D, Green ST, Heslop JM, et al.: Beneficial response to megestrol acetate in AIDS-related cachexia and a possible megestrol withdrawal-associated syndrome? Acta Derm Venereol (Stockh) 1990, 70:520–521.
29. Leinung M, Liporace R, Miller C: Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995, 122:843–845.
30. Mann M, Koller E, Murgo A, et al.: Glucocorticoid-like activity of megestrol: a summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997, 3:1651–1656. Excellent review of an important effect of MA. Clinicians should be aware of the life-threatening potential of adrenal insufficiency. DOI: 10.1001/archinte.157.15.1651
31. Nelson KA, Walsh TD, O’Donovan PB, et al.: Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndrome (CADS). J Palliat Care 1993, 9:27–31.
32. Nelson KA, Walsh TD: The use of metoclopramide in anorexia due to the cancer-associated dyspepsia syndrome (CADS). J Palliat Care 1993, 9:14–18.
33. Berger JR, Pall L, Hall C, et al.: Oxandrolone in AIDS-wasting myopathy. AIDS 1996, 10:1657–1662.
34. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al.: Effect of thalidomide on HIV associated wasting syndrome: a randomized double-blind, placebo-controlled clinical trial. AIDS 1996, 10:1501–1507. DOI: 10.1097/00002030-199611000-00007
35. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al.: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acqui Immun Defic Syndr Hum Retrovirol 1996, 11:247–257.
36. Mellin GW, Katzenstein M: The saga of thalidomide (concluded) neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962, 267:1238–1244. DOI: 10.1056/NEJM196212132672407
37. Tchekmedyian NS: Pharmacoeconomics of nutritional support in cancer. Semin Oncol 1998, 25(suppl:6):62–69.
38. Klein S: Clinical efficacy of nutritional support in patients with cancer. Oncology 1993, 7:87–92.
39. Ask Dr. Weil. Accessed at www.drweil.com. A comprehensive resource on all forms of complementary and alternative medicine with many links to useful sites. It is worth visiting on a regular basis to keep abreast of new developments in the field.
40. National Center for Complementary and Alternative Medicine. Accessed at http://nccam.nih.gov./ This NIH website provides viewers with a complete listing and categorization of the currently reported complementary and alternative techniques. Most physicians would be surprised at the sheer number of methods classified as complementary or alternative. This site deserves attention, particularly by physicians, as it helps to understand the full spectrum of treatments that patients are using or considering.